The hormone is no better than placebo at boosting social behavior in autistic children, according to a new study, but it may still benefit a subset of people with the condition.

The post Intranasal oxytocin ineffective for autism in large trial appeared first on Spectrum | Autism Research News.

After imposing a pause in November 2020, the U.S. Food and Drug Administration has cleared the way for a clinical trial of a gene therapy for Angelman syndrome.

The post Paused Angelman syndrome trial to restart appeared first on Spectrum | Autism Research News.

Preliminary results suggested the treatment is no better than placebo at reducing the severity of core autism traits.

The post French pharma firms terminate trials of bumetanide for autism appeared first on Spectrum | Autism Research News.

Experts question data showing that an experimental therapy that parents deliver to babies with early signs of autism can lessen the intensity of the children’s traits and lower their chances of diagnosis at age 3.

The post Uncertainty clouds test of ‘preemptive’ therapy to ease autism traits appeared first on Spectrum | Autism Research News.

The stubborn lack of treatments for fragile X syndrome — a leading cause of inherited intellectual disability and autism — is spurring researchers to revise clinical trial techniques and revisit old drug candidates.

The post Finding a path forward for fragile X drugs appeared first on Spectrum | Autism Research News.

The finding that MDMA and an experimental serotonin agonist increase sociability across six different model mice suggests that disparate autism-linked mutations converge on the same underlying pathways.

The post Drugs boost serotonin, socialization in multiple autism mouse models appeared first on Spectrum | Autism Research News.

In this edition of Null and Noteworthy, researchers open the case on acetaminophen and close it on oxytocin.

The post Null and Noteworthy: Oxytocin, parental training, outcome assessments appeared first on Spectrum | Autism Research News.